ClinicalTrials.Veeva

Menu

Dairy Lipids and Cardiometabolic Risk (DAILICATE)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Enrolling

Conditions

Morbid Obesity

Treatments

Other: Low-fat dairy products
Other: Milk polar lipid enriched whole-fat dairy products
Other: Whole-fat dairy products

Study type

Interventional

Funder types

Other

Identifiers

NCT05783466
2022-A02415-38 (Other Identifier)
69HCL22_0461

Details and patient eligibility

About

It is a randomized parallel arm intervention study in adults with severe obesity. The objective is to demonstrate that within a dietary handling for weight loss, the daily ingestion during 3 months of whole dairy products enriched with milk polar lipids or whole dairy products decreases to a greater extent fasting plasma apolipoprotein B concentrations than the daily ingestion of low-fat dairy products (control group).

Metabolic parameters will be assessed before and after the 3-month intervention, both at fasting and in postprandial period after the consumption of standardized meals.

Enrollment

75 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men and women between 18-70 years
  • Body Mass Index (BMI) between 35 and 60 kg/m2 inclusive
  • Stable body weight (weight change +/- 5 % for 3 months prior to screening)
  • Consumption of at least 1 serving/day of dairy products made from cow's milk
  • Informed consent

Exclusion criteria

  • History of bariatric or digestive surgery or disease interfering with main outcomes
  • Drinking more than 3 glasses of alcohol per day (>30g/day)
  • Pregnancy, parturiency or breastfeeding
  • Food allergies or intolerance to dairy products
  • Dietary restriction (vegetarian or lactovegetarian) or high protein diet
  • Use of dietary supplements
  • Treated with lipid lowering drugs (fibrates, statins, anti-PCSK9, ezetimibe, cholestyramine) within the last 6 weeks before study entry
  • Treated with insulin, GLP-1 analogs, acarbose, corticoids, beta-blockers.
  • Medications interfering with intestinal microbiota (beta-lactamines within 3 months before the study or laxatives)
  • Smoking ≥ 5 cigarettes/day during the past 6 months.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

75 participants in 3 patient groups

Low-fat dairy products within a dietary handling for weight loss
Other group
Description:
3 servings/day of low-fat dairy products: 1 serving of low-fat cheese, 1 serving of low-fat yogurt and 1 serving of (semi-)skimmed milk.
Treatment:
Other: Low-fat dairy products
Whole-fat dairy products within a dietary handling for weight loss
Experimental group
Description:
3 servings/day of whole-fat dairy products: 1 serving of whole cheese, 1 serving of whole yogurt and 1 serving of whole milk.
Treatment:
Other: Whole-fat dairy products
Whole-fat dairy products enriched with milk polar lipids within a dietary handling for weight loss
Experimental group
Description:
3 servings/day of whole-fat dairy products (1 milk, 1 yogurt, 1 cheese) among which 1 serving/day is enriched with milk polar lipids via butterier.
Treatment:
Other: Milk polar lipid enriched whole-fat dairy products

Trial contacts and locations

2

Loading...

Central trial contact

Emmanuel DISSE, Pr; MArie-Caroline MICHALSKI, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems